Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzastaurin plus docetaxel/prednisone versus placebo plus docetaxel/prednisone in first-line hormone-refractory metastatic prostate cancer
2008-004451-30Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in prostate cancer (PCa) and Metastatic Prostate Cancer (mPC) comparing Enzastaurin arm with Placebo arm (2 arms). Primary endpoint: Objective response rate. Started Aug 2008; status: completed.
02
Drugs
enzastaurin
03
Conditions
prostate cancer (PCa)Metastatic Prostate Cancer (mPC)
Beyond the preview
Go deeper on 2008-004451-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004451-30.